



## **MacuCLEAR and Mystic Pharmaceuticals Agree To Collaborate on Macular Degeneration Phase I/II Clinical Trial**

**AUSTIN, TX – (BUSINESS WIRE) – January 13, 2009—Mystic Pharmaceuticals™, Inc.**  
([www.mysticpharmaceuticals.com](http://www.mysticpharmaceuticals.com))

Mystic Pharmaceuticals announced today it has entered into a collaborative business relationship with MacuCLEAR, Inc. for its upcoming Phase I/II Human Clinical Trials. MacuCLEAR is developing MC 1101, for the treatment and prevention of the progression of Age Related Macular Degeneration (AMD). Mystic Pharmaceuticals, Inc. ('Mystic') has developed a novel unit dose drug delivery platform capable of preservative free, precision delivery of ophthalmic drugs

"We believe Mystic's novel VersiDoser™ delivery system will help overcome many of the challenges of topical delivery of ophthalmic drugs to the eye.", said Philip G. Ralston, Jr., President and CEO of MacuCLEAR. "Standard eyedroppers typically deliver too large a drop that "floods" the eye. Conventional eyedroppers waste product and are difficult for elderly patients to use reliably on a daily basis.. Mystic's individually packaged drops can be precisely sized and accurately delivered with a unique dispenser that is easy to use ." Ralston added, "the Mystic dispenser counts the drops delivered, which will be helpful in tracking compliance and accounting for the usage of a reimbursed product."

Mystic Pharmaceuticals' President and CEO, Timothy Sullivan, stated, "We are pleased to work with MacuCLEAR in their clinical program. Their drug has shown promise throughout its preclinical program and has received fast track status from the FDA. AMD is a growing healthcare problem for our aging population. Our delivery systems are uniquely designed to safely and effectively deliver drugs to low vision and elderly people. The combination of these two technologies offers great potential for addressing a terrible disease resulting in loss of vision."

Ralston and Sullivan jointly announced the collaboration at the OneMedPlace Emerging Healthcare Technologies Finance Forum at the Drake Hotel in San Francisco today.

### **About MacuCLEAR:**

**MacuCLEAR, Inc.** is a specialty pharmaceutical development company, based in Plano, Texas. Its lead compound, MC1101 is a novel, topically delivered solution for the treatment and prevention of the progression of the Dry or early stage of age related macular degeneration, which afflicts 90% of all who have AMD. This technology was invented at Texas A&M University by George C.Y. Chiou, PhD, who led the development of Timolol, a pioneering treatment for glaucoma. For more information please visit the MacuCLEAR website: [www.macuclear.com](http://www.macuclear.com)

**Media Relations contact:** Phillip Ralston, Jr. ([PRalston@macuclear.com](mailto:PRalston@macuclear.com)) +1 (214) 577-5999

### **About Mystic Pharmaceuticals, Inc.**

Mystic Pharmaceuticals™ is an integrated specialty pharmaceutical company based in Austin, Texas. Mystic develops precision unit dose ophthalmic and intranasal drug delivery platforms for pharmaceuticals, biopharmaceuticals and vaccines . Mystic combines its novel drug delivery systems with a pipeline of pharmaceuticals and biologics under development by Mystic or its partners, to meet the expanding global market demand for medications which are lower cost, safer and easier to use for consumers. For more information please visit the Mystic website: [www.mysticpharmaceuticals.com](http://www.mysticpharmaceuticals.com)

**Media relations contact:** Rhonda Davis ([rdavis@mysticpharma.com](mailto:rdavis@mysticpharma.com)) +(1) 512.918.2900 ext. 221